SEC Tracker
Get the app
COCP · XBRL financial data

Cocrystal Pharma financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (COCP's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021†Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue from contracts with customers2,014—————
Research and development6,3078,79412,39215,16912,5375,055
General and administrative5,2935,4275,7455,9905,3413,964
Total operating expenses11,60014,22138,82918,55917,8789,019
Operating income (loss)(9,586)(14,221)(38,829)(18,559)(17,878)(9,019)
Interest expense842(640)(537)(134)
Net income (loss)(9,648)(14,185)(38,837)(17,984)(17,504)(8,831)
Earnings per share, basic USD per share—(0.16)(4.77)(1.87)(1.72)(0.78)
Earnings per share, diluted USD per share——(4.77)(1.87)(1.72)(0.78)
Weighted average shares, basic thousands of shares—7,3648,1439,65110,17411,290
Weighted average shares, diluted thousands of shares——8,1439,65110,17411,290
  • † Share count changed about 1/12 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal years (COCP's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021†Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents33,01058,70537,21926,3539,8607,025
Accounts receivable556—————
Prepaid and other current assets3995682,2431,773430328
Total current assets34,01559,32340,17829,09111,5808,134
Property and equipment, net59145334227115393
Right-of-use asset4984782741,8511,6941,390
Goodwill19,09219,092————
Total assets54,24279,39240,84031,25913,4569,712
Accounts payable6575786141,2221,542890
Total current liabilities1,3581,5451,2163,2622,4282,210
Lease liability, non-current345291571,6131,5051,171
Total liabilities1,7371,8431,2734,8753,9333,381
Accumulated deficit(244,908)(259,093)(297,930)(315,914)(333,418)(342,249)
Total stockholders' equity52,50577,54939,56726,3849,5236,331
Total liabilities and equity54,24279,39240,84031,25913,4569,712
Common shares outstanding (cover page) thousands of shares71,46997,4698,14310,17410,17413,786
  • † Share count changed about 1/12 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal years (COCP's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021†Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(9,648)(14,185)(38,837)(17,984)(17,504)(8,831)
Stock-based compensation662724855801643270
Net cash from operating activities(9,830)(12,719)(21,435)(14,666)(16,485)(8,192)
Purchases of property and equipment2405274118812
Net cash from investing activities(240)(52)(74)(118)(8)(12)
Proceeds from issuing common stock35,78338,505—4,000—154
Net cash from financing activities35,66238,466(27)3,993—5,369
Net change in cash25,59225,695(21,536)(10,791)(16,493)(2,835)
  • † Share count changed about 1/12 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Cocrystal Pharma2,169105(2,516)*19.3M0.9 quarters 10-QJun 30, 2026
Citius Pharmaceuticals17,0081,494(8,678)*27.5M2.0 quarters 10-QJun 30, 2026
Phio Pharmaceuticals12,996not reported(4,035)*11.6M3.2 quarters 10-QJun 30, 2026
Palisade Bio125,172500(7,603)*174.3M16.5 quarters 10-QJun 30, 2026
Cypherpunk Technologies7,624not reported(2,692)*107.8M2.8 quarters 10-QJun 30, 2026
Brainstorm Cell Therapeutics22not reported(895)11.0M0.0 quarters 10-QJun 30, 2026
Cellectar Biosciences33,994not reported(6,010)*9.5M5.7 quarters 10-QJun 30, 2026
Kiora Pharmaceuticals7,077not reported(1,892)*4.4M8.9 quarters 10-QJun 30, 2026
Synergy CHC2925,493(2,045)14.9M0.1 quarters 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.